A patient’s willingness to switch from an originator to biosimilar molecule is influenced by how the physician frames the discussion, specialists in New Zealand have shown. Patients with RA were twice as willing to switch when given a positively framed brief explanation about biosimilars that emphasised the similarities with originator drug, compared to when their ...
Patients are willing to switch to a biosimilar – if the message is right
By Michael Woodhead
17 Jul 2019